Development of a Pharmacist REferral Program in a primary cARE clinic (PREPARE): A prospective cross-sectional study.

TitleDevelopment of a Pharmacist REferral Program in a primary cARE clinic (PREPARE): A prospective cross-sectional study.
Publication TypeJournal Article
Year of Publication2017
AuthorsBarry AR
JournalCan Pharm J (Ott)
Date Published05-06/2017

BACKGROUND: Increasing demand for ambulatory health care services has led to the development of primary care multidisciplinary teams that include pharmacists. The objective of this study was to characterize referrals to a pharmacist in a primary care clinic (PCC) based in Chilliwack, British Columbia.

METHODS: This prospective cross-sectional study included all patients referred to the PCC pharmacist over 12 months (May 2015 to April 2016). Data regarding the source/reason for referral, patient demographics, medical problems/medications and number/category of identified drug therapy concerns (DTCs) were collected.

RESULTS: A total of 137 referrals were received. Mean age was 60 years and 59% were female. Twenty patients (15%) did not attend their appointment. Fifty-eight percent were new clinic patients identified using a Medication Risk Assessment Questionnaire (MRAQ), 30% were from PCC clinicians and 12% were from community family physicians. The most common reason for referral was for a medication review (82%). Median number of medical problems and medications per patient were 7 (interquartile range [IQR] 5) and 11 (IQR 7.5), respectively. A total of 460 DTCs were identified (median 4 per patient, IQR 3.5), of which 34% were medication without an indication and 28% an untreated indication.

DISCUSSION AND CONCLUSION: The most common source of referrals to a PCC pharmacist was for medication reviews of new patients using an MRAQ. Most referred patients had multiple medical problems and polypharmacy, and few were referred for disease-specific management. The number of DTCs per patient was variable and, despite polypharmacy being commonplace, almost one-third of patients had an untreated indication.

Alternate JournalCan Pharm J (Ott)
PubMed ID28507656
PubMed Central IDPMC5415068